Scholar Rock Holding Corporation General and Administrative Expenses 2011-2026 | SRRK

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Scholar Rock Holding Corporation

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
176 M	67.5 M	49.4 M	43.1 M	40.3 M	28.2 M	20.8 M	14.4 M	5.08 M	4.11 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
176 M	4.11 M	44.9 M

Quarterly General and Administrative Expenses Scholar Rock Holding Corporation

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
53.1 M	49.7 M	28.4 M	-	16.1 M	17.1 M	15.3 M	-	13.3 M	12.2 M	10.8 M	-	10.5 M	11.1 M	10.8 M	-	11.3 M	9.26 M	9.37 M	-	8.27 M	6.36 M	5.82 M	-	6.18 M	4.71 M	4.07 M	-	3.17 M	3.46 M	2.32 M	-	1.16 M	1.18 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
53.1 M	1.16 M	12.5 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
AbCellera Biologics ABCL	83.2 M	$ 3.55	-0.42 %	$ 1.06 B	Canada
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
AC Immune SA ACIU	17.9 M	$ 3.25	3.83 %	$ 229 M	Schweiz
I-Mab IMAB	900 M	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
AgeX Therapeutics AGE	9.33 M	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	13.9 M	-	10.36 %	$ 9.8 M	USA
Aptorum Group Limited APM	5.41 M	$ 0.79	0.03 %	$ 4.31 M	China
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
ADC Therapeutics SA ADCT	71.5 M	$ 4.12	-1.9 %	$ 105 M	Schweiz
Arcturus Therapeutics Holdings ARCT	46.1 M	$ 6.55	-1.28 %	$ 179 M	Israel
argenx SE ARGX	308 M	$ 709.08	0.82 %	$ 25 B	Niderland
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Alterity Therapeutics Limited ATHE	5.51 M	$ 3.43	-4.99 %	$ 8.25 B	Australia
Ascendis Pharma A/S ASND	160 M	$ 229.99	-0.45 %	$ 5 B	Danmark
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Atea Pharmaceuticals AVIR	32.9 M	$ 6.09	0.58 %	$ 496 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Athersys ATHX	20.1 M	-	3.77 %	$ 22.4 M	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
AlloVir ALVR	42.9 M	-	4.14 %	$ 49.1 M	USA
BioCardia BCDA	4.4 M	$ 1.29	1.24 %	$ 27.3 M	USA
Anika Therapeutics ANIK	95.8 M	$ 14.55	1.32 %	$ 213 M	USA
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Aptose Biosciences APTO	11.2 M	-	-45.71 %	$ 1.2 M	Canada
AVEO Pharmaceuticals AVEO	60.8 M	-	-	$ 521 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	17.4 M	$ 2.62	-0.75 %	$ 16.5 M	USA
Avenue Therapeutics ATXI	4.64 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	46.7 M	$ 1.51	-	$ 385 M	Britain
Athira Pharma ATHA	26.1 M	-	-	$ 269 M	USA
BioNTech SE BNTX	286 M	$ 94.12	3.95 %	$ 27.2 B	Germany
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Burford Capital Limited BUR	99.3 M	$ 8.27	2.54 %	$ 1.34 B	Britain
AstraZeneca PLC AZN	15.2 B	-	-	$ 96.9 B	Britain
Can-Fite BioPharma Ltd. CANF	3.05 M	$ 3.5	-2.51 %	$ 7.62 B	Israel